Innovative Therapeutics Sorrento Therapeutics offers a broad pipeline of novel therapies including CAR-T, DAR-T, ADCs, oncolytic viruses, and bispecific antibodies, presenting multiple opportunities to collaborate on targeted biopharmaceutical solutions for cancer, autoimmune, and neurodegenerative diseases.

COVID-19 Solutions With active development of antiviral therapies, vaccines, rapid testing devices, and diagnostic tests like COVISTIX and COVITRACK, Sorrento is positioned to expand partnerships in infectious disease testing, vaccine development, and pandemic preparedness markets.

Research & Development Focus Sorrento's ongoing clinical trials and recent positive phase IIa results, especially with Abivertinib, highlight opportunities for joint development or distribution of promising therapeutics targeting mutant EGFR and BTK pathways.

Recent Strategic Moves The company's recent acquisitions, such as Virexhealth, and significant funding efforts including a $75M debtor-in-possession financing, indicate growth potential and openness to partnerships that can leverage their expanding portfolio and infrastructure.

Market Expansion Potential With a sizeable workforce and revenue scale, along with active legal and financial strategies, Sorrento presents sales prospects across biotech, pharma, and diagnostics sectors seeking innovative, diverse, and COVID-related health solutions.